Table 1.

Association of PAQR5 expression with clinicopathological parameters in ccRCC patients.

Characteristic	Low PAQR5	High PAQR5	p	statistic	method
n	269	270
T stage, n (%)			<0.001	45.84	Chisq.test
T1	101 (18.7%)	177 (32.8%)
T2	43 (8%)	28 (5.2%)
T3	115 (21.3%)	64 (11.9%)
T4	10 (1.9%)	1 (0.2%)
N stage, n (%)			0.023	5.18	Chisq.test
N0	117 (45.5%)	124 (48.2%)
N1	13 (5.1%)	3 (1.2%)
M stage, n (%)			<0.001	14.86	Chisq.test
M0	197 (38.9%)	231 (45.7%)
M1	55 (10.9%)	23 (4.5%)
Pathologic stage, n (%)			<0.001	44.51	Chisq.test
Stage I	98 (18.3%)	174 (32.5%)
Stage II	34 (6.3%)	25 (4.7%)
Stage III	77 (14.4%)	46 (8.6%)
Stage IV	58 (10.8%)	24 (4.5%)
Gender, n (%)			0.016	5.83	Chisq.test
Female	79 (14.7%)	107 (19.9%)
Male	190 (35.3%)	163 (30.2%)
Histologic grade, n (%)			<0.001	40	Chisq.test
G1	4 (0.8%)	10 (1.9%)
G2	96 (18.1%)	139 (26.2%)
G3	106 (20%)	101 (19%)
G4	61 (11.5%)	14 (2.6%)
OS event, n (%)			<0.001	37.44	Chisq.test
Alive	149 (27.6%)	217 (40.3%)
Dead	120 (22.3%)	53 (9.8%)
DSS event, n (%)			<0.001	50.43	Chisq.test
Alive	175 (33.1%)	245 (46.4%)
Dead	87 (16.5%)	21 (4%)
PFI event, n (%)			<0.001	46.29	Chisq.test
Alive	152 (28.2%)	226 (41.9%)
Dead	117 (21.7%)	44 (8.2%)
Age, median (IQR)	61 (53, 70)	60 (51, 69)	0.310	38151	Wilcoxon